These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 31718534

  • 1. The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease.
    Gaultier GN, McCready W, Ulanova M.
    BMC Immunol; 2019 Nov 12; 20(1):41. PubMed ID: 31718534
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naïve and previously immunized adult patients with severe chronic kidney disease.
    Ulanova M, Huska B, Desbiens A, Gaultier GN, Domonkos V, McCready WG.
    Vaccine; 2021 Jan 22; 39(4):699-710. PubMed ID: 33358702
    [Abstract] [Full Text] [Related]

  • 3. Opsonophagocytic activity against Streptococcus pneumoniae in Indigenous and non-Indigenous patients with severe chronic kidney disease immunized with 13-valent pneumococcal conjugate vaccine.
    Ulanova M, Huska B, Dubois S, McCready W.
    Vaccine; 2022 Jul 30; 40(32):4594-4602. PubMed ID: 35738971
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity and Immunological Memory Induced by the 13-Valent Pneumococcal Conjugate Followed by the 23-Valent Polysaccharide Vaccine in HIV-Infected Adults.
    Farmaki PF, Chini MC, Mangafas NM, Tzanoudaki MT, Piperi CP, Lazanas MZ, Spoulou VS.
    J Infect Dis; 2018 Jun 05; 218(1):26-34. PubMed ID: 29722823
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
    Vadlamudi NK, Parhar K, Altre Malana KL, Kang A, Marra F.
    Vaccine; 2019 Feb 14; 37(8):1021-1029. PubMed ID: 30685252
    [Abstract] [Full Text] [Related]

  • 6. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report.
    Pasiarski M, Rolinski J, Grywalska E, Stelmach-Goldys A, Korona-Glowniak I, Gozdz S, Hus I, Malm A.
    PLoS One; 2014 Feb 14; 9(12):e114966. PubMed ID: 25506837
    [Abstract] [Full Text] [Related]

  • 7. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up.
    Kantsø B, Halkjær SI, Østergaard Thomsen O, Belard E, Gottschalck IB, Jørgensen CS, Krogfelt KA, Slotved HC, Ingels H, Petersen AM.
    Infect Dis (Lond); 2019 Sep 14; 51(9):651-658. PubMed ID: 31290715
    [Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Peterson JT, Stacey HL, MacNair JE, Li J, Hartzel JS, Sterling TM, Benner P, Tamms GM, Musey LK.
    Hum Vaccin Immunother; 2019 Sep 14; 15(3):540-548. PubMed ID: 30427749
    [Abstract] [Full Text] [Related]

  • 9. Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination.
    van den Biggelaar AHJ, Richmond PC, Fuery A, Anderson D, Opa C, Saleu G, Lai M, Francis JP, Alpers MP, Pomat WS, Lehmann D.
    PLoS One; 2017 Sep 14; 12(10):e0185877. PubMed ID: 29028802
    [Abstract] [Full Text] [Related]

  • 10. Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with β-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine.
    Papadatou I, Piperi C, Alexandraki K, Kattamis A, Theodoridou M, Spoulou V.
    Clin Infect Dis; 2014 Sep 15; 59(6):862-5. PubMed ID: 24879786
    [Abstract] [Full Text] [Related]

  • 11. Natural immunity against Haemophilus influenzae type a and B-cell subpopulations in adult patients with severe chronic kidney disease.
    Gaultier GN, McCready W, Ulanova M.
    Vaccine; 2019 Jun 19; 37(28):3677-3684. PubMed ID: 31122854
    [Abstract] [Full Text] [Related]

  • 12. No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.
    Licciardi PV, Toh ZQ, Clutterbuck EA, Balloch A, Marimla RA, Tikkanen L, Lamb KE, Bright KJ, Rabuatoka U, Tikoduadua L, Boelsen LK, Dunne EM, Satzke C, Cheung YB, Pollard AJ, Russell FM, Mulholland EK.
    J Allergy Clin Immunol; 2016 Jun 19; 137(6):1772-1779.e11. PubMed ID: 26825000
    [Abstract] [Full Text] [Related]

  • 13. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease.
    Kantsø B, Halkjær SI, Thomsen OØ, Belard E, Gottschalck IB, Jørgensen CS, Krogfelt KA, Slotved HC, Ingels H, Petersen AM.
    Vaccine; 2015 Oct 05; 33(41):5464-5469. PubMed ID: 26275480
    [Abstract] [Full Text] [Related]

  • 14. Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.
    Wijmenga-Monsuur AJ, van Westen E, Knol MJ, Jongerius RM, Zancolli M, Goldblatt D, van Gageldonk PG, Tcherniaeva I, Berbers GA, Rots NY.
    PLoS One; 2015 Oct 05; 10(12):e0144739. PubMed ID: 26658902
    [Abstract] [Full Text] [Related]

  • 15. Immune response to pneumococcal conjugate vaccination in asplenic individuals.
    Stanford E, Print F, Falconer M, Lamden K, Ghebrehewet S, Phin N, Baxter D, Helbert M, McCann R, Andrews N, Balmer P, Borrow R, Kaczmarski E.
    Hum Vaccin; 2009 Feb 05; 5(2):85-91. PubMed ID: 18758242
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions.
    Jallow S, Madhi SA, Madimabe R, Sipambo N, Violari A, Kala U, Petersen K, Naidoo S, Verwey C, Moore DP, Nunes MC.
    Vaccine; 2017 Aug 03; 35(34):4321-4329. PubMed ID: 28688781
    [Abstract] [Full Text] [Related]

  • 17. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC).
    MMWR Recomm Rep; 2010 Dec 10; 59(RR-11):1-18. PubMed ID: 21150868
    [Abstract] [Full Text] [Related]

  • 18. Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine.
    van Westen E, Wijmenga-Monsuur AJ, van Dijken HH, van Gaans-van den Brink JA, Kuipers B, Knol MJ, Berbers GA, Sanders EA, Rots NY, van Els CA.
    Clin Infect Dis; 2015 Aug 01; 61(3):342-9. PubMed ID: 25838290
    [Abstract] [Full Text] [Related]

  • 19. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M, Abboud MR, Fiquet A, Inati A, Lebensburger JD, Kaddah N, Mokhtar G, Piga A, Halasa N, Inusa B, Rees DC, Heath PT, Telfer P, Driscoll C, Al Hajjar S, Tozzi A, Jiang Q, Emini EA, Gruber WC, Gurtman A, Scott DA.
    Pediatr Blood Cancer; 2015 Aug 01; 62(8):1427-36. PubMed ID: 25810327
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
    Bhorat AE, Madhi SA, Laudat F, Sundaraiyer V, Gurtman A, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
    AIDS; 2015 Jul 17; 29(11):1345-54. PubMed ID: 25888646
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.